Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — JP Morgan 36th Annual Healthcare Conference (January 2018)
23 slides from Halozyme Therapeutics's conference presentation, Jan 10, 2018
Slide 1: Building a Premier Oncology Biotech
Building a Premier Oncology Biotech Dr. Helen Torley, President & CEO January 9, 2018 JP Morgan 36th Annual Healthcare Conference
Slide 2: Forward-Looking Statements
Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include possible activity, benefits and attr
Slide 3: Halozyme Two Pillar Strategy
Halozyme Two Pillar Strategy 2 Removing Biological Barriers to Treatment Enhancing Delivery of Treatments Late Stage Investigational New Product ENHANZE® PEGPH20 ENHANZE image from “The 5 Steps to Infuse HYQVIA.” http://www.hyqvia.com/resources/videos/
Slide 4: Significant Value Creation in 2017
Significant Value Creation in 2017 ENHANZE® • 2 new partners: BMS, Alexion • Roche adds new target • $175M upfront milestones • Phase 3 starts: Janssen’s Darzalex® 3 PEGPH20 - Pancreatic • Supportive Phase 2 • Companion Diagnostic • Strong progress in Phase 3 trial: HALO-301 PEGPH20 - Pan-Tumor • >
Slide 5: ENHANZE Pillar
_® " YP rctozyme ENHANZE® Pillar
Slide 6: 2017: Transformative Year for ENHANZE Pipeline
2017: Transformative Year for ENHANZE® Pipeline June 2017: RITUXAN HYCELA™ U.S. FDA Approval Aug 2017: Initiate Phase 1 trial Sept 2017: Landmark 11-target I-O deal Sept 2017: Expanded collaboration, 1 new target Nov 2017: Initiate Phase 3 trials, daratumumab SC Dec 2017: Four-target collaboration 5
Slide 7: Commercial Products Driving Robust ENHANZE Royalty Growth
1 Quarterly reporting lag in 2017; expect to see revenue reflected in 2018. 2 2017 total royalty revenue, unaudited. Commercial Products Driving Robust ENHANZE® Royalty Growth $9M $31M $51M $64M2 2013 2014 2015 2016 2017 Growing Royalty Revenue Average Mid-Single Digit Royalty Rate Across Partnershi
Slide 8: ENHANZE: ~$1 Billion Royalty Revenue Potential in 2027
Approved Products Potential Future Products1,2 Assumes 7 additional products, including Darzalex® and Opdivo®, are globally approved and launched in multiple indications ENHANZE®: ~$1 Billion Royalty Revenue Potential in 2027 1 Includes projections for subcutaneous versions of 7 targets not approved
Slide 9: ENHANZE Progress and Value Acceleration in 2018
Approved and Commercialized Phase 1 Phase 3 ENHANZE® Progress and Value Acceleration in 2018 2018 2017 1 Darzalex® 2 Perjeta ®/Herceptin® Anti-IL23 3 4 6 Products 9 products 8 2 3
Slide 10: Potential for Competitive Differentiation
Potential for Competitive Differentiation New Intellectual Property and Exclusivity Changing US Reimbursement and Care Landscape Reduced Treatment Burden and Healthcare Costs ENHANZE® Offers Four Paths for Differentiation and Value Creation for Partners 9 1 2 3 4
Slide 11: Oncology Asset: PEGPH20
Phase 3 Oncology Asset: PEGPH20
Slide 12: Pancreatic Ductal Adenocarcinoma (PDA): The Need
1 SEER 18 2006-2012, Globocan 2012, DRG Epidemiology data. 2 Statistics adapted from the American Cancer Society's publication, Cancer Facts & Figures 2016. 3 Rahib et al, Cancer Res 2014. 4 Whatcott, et al. AACR (2013) Pancreatic Ductal Adenocarcinoma (PDA): The Need • 65,000 people diagnosed with
Slide 13: PEGPH20 Targets and Degrades Hyaluronan
1 Provenzano, et al. Cancer Cell. 2012,21(3):418. PEGPH20 Targets and Degrades Hyaluronan Before PEGPH201 • Hard • Fibrotic • Hypovascular MPA#1 + Gemcitabine fter PEGPH201 • Soft • Cellular • Hypervascular 12
Slide 14: ~$1B Potential Sales Opportunity in HA-High Metastatic PDA
1 SEER 18 2006-2012, Globocan 2012, DRG Epidemiology data. 2 Halozyme estimates for HA-High %. 3 DRG Epidemiology data, Halozyme internal estimates. ~$1B Potential Sales Opportunity in HA-High Metastatic Pancreatic Ductal Adenocarcinoma (PDA) 13 Diagnosed Metastatic PDA Annually US and EU 51 Estimat
Slide 15: PEGPH20 Pancreas Cancer Program De-risking Event Timeline
PEGPH20 Pancreas Cancer Program De-risking Event Timeline 14 2013–2015 • Phase 2 HALO-202 study initiated 2016 • Companion Diagnostic algorithm and cutpoint established • Initiated Phase 3 HALO-301 study 2017 • HALO-202 data supportive of Phase 3 trial design • Validated companion diagnostic • HALO-
Slide 16: HALO-301 Pancreatic: Global Phase 3 Trial
HALO-301|Pancreatic: Global Phase 3 Trial Enrolling in 22 Countries • Randomized (2:1 PAG:AG), double-blind, placebo-controlled, global • Project to achieve target number of PFS events late Q4 2018, triggering final data collection, cleaning and interim analysis PEGPH20 + ABRAXANE® + gemcitabine (PA
Slide 17: Estimated Annual HA-High Patients in Multiple Tumor Types
1 DRG Epidemiology data, Halozyme estimate for HA-High %. 1L Metastatic Lung Cancer 87,000 1L Metastatic Pancreas Cancer 25,000 1L Metastatic Gastric Cancer 22,000 Estimated Annual HA-High Patients in Multiple Tumor Types1 1L Metastatic Cholangiocarcinoma, Gall Bladder Cancer 7,000 140,000 Total Pat
Slide 18: Robust Pan-Tumor Testing of PEGPH20
ISTs: SWOG study enrollment closed in March 2017 following futility analysis in all-comer population. Data collection and analysis ongoing. Breast Cancer Gastric Cancer, NSCLC Pancreas Cancer, Gastric Cancer Gall Bladder Cancer, Cholangiocarcinoma Robust Pan-Tumor Testing of PEGPH20 17 1 Pending con
Slide 19: Financial Update
_® " YP rctozyme Financial Update
Slide 20: Record 2017 Financial Performance
Record 2017 Financial Performance Jan 2017 2017 FY Estimate Net Revenue $115M to $130M $310M to $320M New ENHANZE® agreements: $172M Operating Expenses $240M to $250M $230M to $240M Disciplined expense control, flat spending to 2016 Operating Cash (Burn) / Flow ($75M to $85M) $125M to $135M Excludes
Slide 21: 2018 Financial Guidance
2018 Financial Guidance 2018 Net Revenue • Royalty Growth • Product Sales $115M to $125M 25% - 30% API product orders lower as a result of planned partner manufacturing transition • Does not include potential new ENHANZE® agreements Operating Expenses $230M to $240M • Disciplined expense control, fl
Slide 22: Core Elements of Value Creation in 2018
Core Elements of Value Creation in 2018 ENHANZE® • 25%-30% Royalty Revenue Growth • Multiple catalysts – 3 Phase 1 starts – 4 Phase 3 Darzalex® trials • ~$1B royalty potential in 2027 21 PEGPH20 - Pancreatic • Q4 2018 Phase 3 PFS Events milestone • ~$1B potential sales opportunity PEGPH20 - Pan-Tumo
Slide 23: Building a Premier Oncology Biotech
Building a Premier Oncology Biotech Dr. Helen Torley, President & CEO January 9, 2018 JP Morgan 36th Annual Healthcare Conference
Halozyme Therapeutics — JP Morgan 36th Annual Healthcare Conference (January 2018) on 6ix